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Sir,
In the 20 October 2003 issue, Aparicio et al (2003) reported
about 66 patients with metastasic colorectal cancer aged from 75 to
88 (median, 78) treated with oxaliplatin or irinotecan in
combination with either 5-fluorouracil or raltitrexed. The authors
state on the feasibility of these regimens in the elderly population.
The first point is the limited recruitment by 12 centres during
more than 3 years, suggesting highly selected population. It would
have been interesting to estimate the proportion of patients
receiving no chemotherapy. The main point is the high grade III or
IV toxicity rate of 42%. Given the prognosis and cost of these
drugs, is this acceptable? Although efficacy is a major goal in some
situations including candidates to metastasectomy or parents of
young children, chemotherapy remains palliative in nearly all
cases. Significant increased toxicity has previously been found in
patients aged over 65 years in two phase II study of irinotecan
(Rougier et al, 1997; Rothenberg et al, 1999). Increased toxicity is
logically observed in elderly patients given numerous pharmaco-
kinetic changes, including loss of total body water, increased total
body fat, or decreased albumin (Wallace and Verbeck, 1983).
Oxaliplatin is intensively bound on the erythrocytes (Pendyala and
Creaven, 1993). The albumin protein binding for oxaliplatin and
SN-38, the active metabolite of irinotecan is greater than 90%.
Thus, the volume of distribution may be also increased by anaemia
or hypoalbuminaemia. The glomerular filtration rate progressively
declines by about 1% each year after the age of 40 years (Evers et al,
1995). Thus, dose adaptation of drugs with renal elimination has
been proposed in case of creatinine clearance lower than
60mlmin
1 (Kintzel and Dorr, 1995). The mean creatinine
clearance was about 57mlmin
1 in the present study. Polyphar-
macy also is a major concern. Certain treatments of comorbid
illnesses may interfere with chemotherapy, in particular for
cytochrome P-450 enzyme or conjugation reactions. Irinotecan is
extensively metabolised by the cytochrome P-450 isoenzymes
CYP3A4 and CYP3A5 (Santos et al, 2000). For example, CYP3A4
can be induced by carbamazepin or phenytoin and inhibited by
macrolides or antifungal imidazoles (Balis, 1986). Numerous
drugs such as warfarin, phenytoin or salicylates may displace
chemotherapeutic agents from albumin binding sites (Spina
and Scordo, 2002). In other words, standard full-dose
regimen represents overdosage in a wide fraction of this
population. Hepatic impairment due to liver involvement
might be a particular concern. Bilirubin might compete with
chemotherapeutic agents for albumin binding. Significant
elevations in transaminases have been reported under raltitrexed,
particularly in case of hepatic metastases or abnormal baseline
transaminases levels (Cocconi et al, 1998). The liver intervenes
by many aspects in the metabolism of irinotecan and
SN38, implicating the cytochromes, glucuro-conjugation by
UDP-glucuronosyltransferase 1A1 (UGT1A1) and enterohepatic
cycling, resulting in wide interpatient variability (Rivory, 2000).
High bilirubin and alkaline phosphate levels are associated with
toxicity (Raymond et al, 2002). Severe toxicity also has been
observed in patients with unconjugated hyperbilirubinaemia due
to UGT1A1 deficiency (Wasserman et al, 1997) encountered in
Gilbert’s syndrome (5% of the population). Although the present
study demonstrates significant efficacy in elderly patients,
chemotherapy must be adapted to the diversity of the elderly
population. In line with this, certain measures potentially could
decrease toxicity such as the adaptation of comedications or
correction of anaemia and hypoalbuminaemia. Alkalisation might
prevent irinotecan-induced diarrhoea by orientating the intestinal
metabolism of SN-38 towards carboxylate form (Ikegami et al,
2002).
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Sir,
Dr Alliot and Barrios pointed out that our results have been
obtained in selected elderly patients. We did not evaluate the
number of elderly patients who were candidates for oxaliplatin or
irinotecan chemotherapy but did not receive it. Nevertheless, two
French studies estimate that only 8–17% of patients over 75 years
with advanced colorectal cancer received palliative chemotherapy
(Mitry et al, 2003; Navazesh et al, 2003). Few elderly patients are
referred to the oncologist for various reasons (Mahoney et al,
2000). In our study, the patients have few comorbidities and we
concluded that chemotherapy with oxaliplatin or irinotecan is
feasible in fit elderly patients.
The overall rate of grade III and IV toxicity appears too high
to be acceptable for Dr Alliot and Barrios. Nevertheless, only
17% of the patients stopped the treatment because of the
toxicity and no toxic death occurred after the 545 cycles
analysed. Moreover, the observed toxicity rate was similar to
that observed in younger patients treated with these drugs
in a palliative situation (de Gramont et al, 2000; Douillard
et al, 2000). The toxicity of irinitocan is related to the
administration schedule even in young patients. The two phase
II studies cited by Alliot and Barrios (Rougier et al, 1997;
Rothenberg et al, 1999) investigated weekly or 3-weekly irinotecan
monotherapy schedule. The weekly regimen is more toxic than the
biweekly schedule and dose reduction is less frequent in the latter
(Douillard et al, 2000).
The mean haemoglobin level was in the lower bound of the
normal range, creatinin clearance was reduced in our patients and
especially in those aged over 80, as it is presented in Table 1.
Bilirubin was increased in 9% of the patients and alkaline
phosphatase increased more than 2 N in 15% of the patients.
Nevertheless, neither haemoglobin level, creatinin clearance,
alkaline phosphatase nor bilirubin level were associated with
increased toxicity in our patients (data not shown). It must be
pointed out that patients with a Charlson score 42 had more
treatment interruption for toxicity.
We agree with Dr Alliot and Barrios that albumin level and
polypharmacy may interfere with chemotherapy and that a dose
reduction should be done in some cases. In our study, only six
(9%) patients had a dose reduction from the first cycle, a severe
toxicity occurred in only one (17%) of these patients. Early toxicity
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